I strongly recommend you don’t invest in Clinuvel at all.... I’m...

I strongly recommend you don’t invest in Clinuvel at all.... I’m confident that Clinuvel know a lot more about what they are doing than what you presume to know. XP and variagate porphyria are boons, and I’m quite sure they will be insurance companies in the US that will cover vitiligo, especially when the per unit price is reduced substantially ($500-2k). An inflection point will occur where the per unit price is affordable to everyone and suddenly the drug becomes available to large swaths of the population. Then there’s offlabel...

The irony here is there are many pharmaceuticals in the world running up substantial losses and drugs in Phase 1-2 with over the top share prices that aren’t justified in any sense. Clinuvel however has a drug in the European market with 40% yoy growth, $48-50 million cash in hand, and zero debt which more than justifies a potentially elevated share price. Say what you will about Clinuvel, but the potential is too enormous to foolishly ignore.